
2seventy bio, Inc. (NASDAQ: TSVT), relating to the proposed merger with Bristol Myers Squibb. Under the terms of the agreement, Bristol Myers Squibb will acquire 2seventy bio, with 2seventy shareholders receiving $5.00 per share in cash.
2seventy bio, Inc. (NASDAQ: TSVT), relating to the proposed merger with Bristol Myers Squibb. Under the terms of the agreement, Bristol Myers Squibb will acquire 2seventy bio, with 2seventy shareholders receiving $5.00 per share in cash.